Navigation Links
Biomedical researchers receive Hartwell Foundation awards
Date:5/2/2012

Two faculty members from the University of California, Davis, are among 12 scientists selected to receive Individual Biomedical Research Awards from The Hartwell Foundation this year. The awards provide $100,000 of direct support each per year for three years, as well as videoconferencing equipment for periodic communications with the foundation and other award recipients. The foundation is also funding a UC Davis Hartwell Foundation postdoctoral researcher with $50,000 per year over two years.

The awardees are: Frederic Chedin, associate professor in the Department of Molecular and Cellular Biology, College of Biological Sciences; Noriko Satake M.D., assistant professor of pediatrics in the UC Davis School of Medicine and Comprehensive Cancer Center; and Paula Goines, postdoctoral researcher in the Department of Molecular Biosciences in the UC Davis School of Veterinary Medicine.

In 2011, The Hartwell Foundation designated UC Davis as one of its Top Ten Centers for Biomedical Research. Including Chedin and Satake, the foundation has made Individual Biomedical Research Awards to five UC Davis scientists and engineers since 2009.

The prestigious designation in 2012 also meant that UC Davis received a Hartwell Fellowship to fund one postdoctoral researcher, chosen by the university, who exemplifies the values of the foundation. The fellowship award is intended to support scientists in the early stages of biomedical research careers by enabling them to pursue further specialized training. Goines is the first fellowship recipient from UC Davis.

"The foundation is impressed with the manner in which UC Davis has embraced the Hartwell process to inspire innovation and achievement. UC Davis' leadership exceeded our expectations by their collegial participation to identify outstanding proposals from interested faculty and win two awards this year," said Fred Dombrose, president of The Hartwell Foundation.

Chedin will use the funds to explore a novel approach to understanding a common autoimmune disease, systemic lupus erythematosus, in which the body's immune system attacks itself, including making antibodies against DNA.

At any time, most of our DNA is "silenced" or switched off by a chemical modification, except at a few specific sites, called CG islands, which serve as "on" switches for our genes. Chedin's lab has been studying how these CG islands are protected from silencing; he thinks that too little silencing might play a role in the development of systemic lupus.

He will test his hypothesis by using as a model system the severe but rare autoimmune disorder called Aicardi-Goutires syndrome, which mimics early onset lupus. The syndrome affects infants, and in most cases leads to death by age 10 to 15. Understanding the biological mechanisms that underlie Aicardi-Goutires will generate critical insights into how the innate immune system can be triggered. If Chedin is successful, his efforts will lead to the development of new diagnostic tests and therapies for children affected with early onset lupus and related autoimmune diseases.

Satake is working to develop a new method to treat childhood leukemia, called molecular targeting. The approach is different from conventional chemotherapy drugs, which kill healthy blood cells and leukemic cells equally. Satake proposes to develop a unique method to deliver a type of molecule that interferes with gene expression, called siRNA. She seeks to deliver it specifically to the leukemia cells, but not to normal healthy cells. If she is successful, her narrow-target approach could prove a transformative pediatric cancer treatment.

Satake explained that while considerable gains have been made in curing pediatric cancers, there are still lethal forms of the disease that resist treatment.

"Even when we cure the cancer, many of those patients are known to have significant long-term side effects or late effects derived from radiation and chemotherapy that can cause heart failure, osteoporosis, learning disabilities and even secondary cancer," she said. "Unfortunately, those are irreversible. The new targeted therapy to be developed will not only be more effective in treating cancers but also have fewer side effects to normal cells than current therapies."

Goines is a recent Ph.D. graduate from UC Davis. She will work with Pamela Lein, professor of neurotoxicology in the Department of Molecular Biosciences, on a new approach to studying autism by looking at nerve cells grown from adult stem cells present in the hair follicles of patients.

In the Hartwell competition, all nominees submit a detailed research proposal, are personally interviewed and make a formal presentation of their proposed research. In selecting awardees, The Hartwell Foundation takes into account the nature of the proposed innovation, the extent to which a strategic or translational approach might promote rapid clinical application of research results, the supportive role and extent of collaboration in the proposed research, the institutional commitment to provide encouragement and technical support to the investigator, and the extent to which funding the investigator will make a difference.


'/>"/>

Contact: Andy Fell
ahfell@ucdavis.edu
530-752-4533
University of California - Davis
Source:Eurekalert

Related medicine news :

1. First Annual Bay Area Biomedical Device Conference to be Held at San Jose State University
2. New Diagnostic Testing Company, Blue Ocean Biomedical, Specializes In Automated, Load & Go Cell Analysis Systems For Immune Monitoring
3. Manmade antibodies hold biomedical promise
4. Blue Ocean Biomedical Opens New Manufacturing Facility In Miramar, FL
5. How badly does it hurt? Research examines the biomedical diagnosis of pain
6. UC San Diego receives 2 major biomedical informatics grants
7. VA names UCI orthopedic biomedical engineer a senior research career scientist
8. Updating ethical guidelines for biomedical engineering
9. AADR applauds President Obamas support for maintaining biomedical research in FY11
10. UCSD scientists receive prestigious Hartwell Biomedical Research Awards
11. Leading research organizations announce top-tier journal for biomedical and life sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... ... June 23, 2017 , ... "The Better ... ultimately do significant harm to people with all chronic conditions, including mental illnesses, ... leaves in place the Affordable Care Act (ACA) requirement that insurers cover pre-existing ...
(Date:6/23/2017)... ... 2017 , ... Dr. Ran Y. Rubinstein , a ... offering three new minimally invasive procedures to patients who want a younger and ... Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich plasma (PRP) ...
(Date:6/23/2017)... ... June 23, 2017 , ... Ensuring meat products ... videos highlight the importance of correctly using a meat thermometer. The videos feature ... extensive research on consumer food safety habits. Dr. Bruhn explains the variety of ...
(Date:6/23/2017)... ... June 23, 2017 , ... ... Flood Insurance offerings. With the Federal Emergency Management Agency’s (FEMA) recent update of ... United States. In 2012, the Biggert-Waters Act was enacted to reflect the actual ...
(Date:6/23/2017)... Gilmer, TX (PRWEB) , ... June 23, 2017 , ... ... consultations to residential and business clients throughout eastern Texas, is announcing the launch of ... , Recent breast cancer statistics in the United States reveal that an estimated ...
Breaking Medicine News(10 mins):
(Date:5/30/2017)... May 30, 2017 DarioHealth Corp. (NASDAQ: DRIO), a leading ... today announced that it will be presenting at the 7th annual ... PT. Erez Raphael , CEO, of DarioHealth will be giving ... be held on June 6th & 7th, 2017 at the Luxe ... small / micro-cap space. About ...
(Date:5/26/2017)... plc (NASDAQ: ENDP ) announced today that ... in a fireside chat at Goldman Sachs, 38 th ... 10:40 a.m. PT / 1:40 p.m. ET. The conference will ... Verdes, CA. A live webcast and ... Company,s website at http://www.endo.com/investors/overview . Participants should allow approximately ...
(Date:5/22/2017)... COTTAGE, N.Y. , May 22, 2017 /PRNewswire/ ... antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of a ... plain English, the results of a clinical study ... one year treatment with Gene-Eden-VIR/Novirin in individuals suffering ... important to note that there are no other ...
Breaking Medicine Technology: